Erdafitinib with or without immunotherapy for FGFR-altered bladder cancer
Part of Cancer clinical trials.
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have muscle-invasive bladder cancer (stage T2–T4aN0/N1M0), confirmed by a biopsy or surgery within the last 3 months.
- Your tumor is mostly (≥50%) urothelial (transitional cell) carcinoma.
- You are age 18 or older and have a good ability to perform daily activities (ECOG 0-1).
- You cannot or choose not to receive cisplatin-based chemotherapy.
- Your tumor has a specific change in the FGFR gene (found through a tissue biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of a targeted drug (disitamab vedotin) and an immunotherapy (toripalimab) before surgery for bladder cancer that has grown into the muscle. The goal is to see if this combination works better than the standard chemotherapy plus immunotherapy approach.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests a combination of two drugs—an antibody-drug conjugate (a targeted therapy that delivers cancer-killing medicine directly to cells) and an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo works better than the standard chemoradiotherapy for bladder cancer when you keep your bladder.
This trial tests a combination of two drugs—pemigatinib, which targets tumors with certain FGFR gene changes, and an immunotherapy drug that helps the immune system fight cancer—for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.